SEARCH

SEARCH BY CITATION

References

  • 1
    Armonis A, Patch D, Burroughs AK. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? HEPATOLOGY 1997; 25: 245248.
  • 2
    Vorobioff J, Groszmann RJ, Pibacea E, Gamen M, Villavicencio R, Bordato J, Morel I, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 111: 701709.
  • 3
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. HEPATOLOGY 2003; 37: 902908.
  • 4
    Boyer TD, Triger DR, Horisawa M, Redeker AG, Reynolds TB. Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology 1977; 72: 584589.
  • 5
    Perelló A, Escorsell A, Bru C, Gilabert R, Moitinho E, García-Pagán JC, Bosch J. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. HEPATOLOGY 1999; 30: 13931397.
  • 6
    Lin HC, Tsai YT, Lee FY, Chang TT, Wang SS, Lay CS, Lee SD, et al. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis. J Hepatol 1989; 9: 326330.
  • 7
    Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003; 38 (Suppl 1): S5468.
  • 8
    Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rhodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 10561059.
  • 9
    Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 16241629.
  • 10
    Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647655.
  • 11
    Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 14011407.
  • 12
    Viallet A, Joly JG, Marleau D, Lavoie P. Comparison of free portal venous pressure and wedged hepatic venous pressure in patients with cirrhosis of the liver. Gastroenterology 1970; 59: 372375.
  • 13
    Lebrec D, De Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980; 79: 11391144.
  • 14
    Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. HEPATOLOGY 1985; 5: 419424.
  • 15
    McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs hemodynamic response to drugs in portal hypertension. J Hepatol 1998; 28: 10151019.
  • 16
    Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C, Burroughs AK. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 10131019.
  • 17
    Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis [letter]. J Hepatol 1991; 12: 124125.
  • 18
    Escorsell A, Bordas JM, Castañeda B, Llach J, García-Pagán JC, Rodés J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. HEPATOLOGY 2000; 31: 10611067.
  • 19
    Bureau C, Péron JM, Alric L, Morales J, Sanchez J, Barange K, Payen JL, et al. “A la carte” treatment of portal hypertension : adapting medical therapy to hemodynamic response for the prevention of bleeding. HEPATOLOGY 2002; 36: 13611366.
  • 20
    De BK, Sen S, Biswas PK, Sengupta D, Biswas J, Santra A, Hazra B, et al. Propranolol in primary and secondary prophylaxis of variceal bleeding among cirrhotics in India: a hemodynamic evaluation. Am J Gastroenterol 2000; 95: 20232028.
    Direct Link:
  • 21
    Thalheimer U, Mela M, Patch D, Burroughs AK. Prevention of variceal rebleeding [letter]. Lancet 2003; 361: 22442245.
  • 22
    Bosch J, García-Pagán JC. Prevention of variceal rebleeding. Lancet 2003; 361: 952954.
  • 23
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. HEPATOLOGY 2000; 32: 930934.
  • 24
    Hicken BL, Sharara AI, Abrams GA, Eloubeidi M, Fallon MB, Arguedas MR. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Aliment Pharmacol Ther 2003; 17: 145153.
  • 25
    Feu F, Bordas JM, Luca A, García-Pagán JC, Escorsell A, Bosch J, Rodés J. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygous blood flow in patients with cirrhosis. HEPATOLOGY 1993; 18: 10821089.
  • 26
    García-Pagán JC, Bosch J. Prevention of variceal bleeding [letter]. Lancet 2003; 361: 2245.
  • 27
    The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicentric study. N Engl J Med 1988; 319: 983989.
  • 28
    Cales P. Factors associated with failure of propranolol for the prevention of first bleeding in cirrhotic patients. The study group of primary prophylaxis. Gastroenterol Clin Biol 1992; 16: 504510.
  • 29
    Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991; 324: 15321538.
  • 30
    Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodes J, Wright SC, Matloff DS, et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: a multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. HEPATOLOGY 1991; 13: 902912.
  • 31
    Vorobioff J, Picabea E, Villavicencio R, Puccini V, Rossi O, Bordato J, Audano M. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. HEPATOLOGY 1987; 7: 648653.
  • 32
    Powell WJ, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal and possible effects of recent changes in general management of the disease. Am J Med 1968; 44: 406420.
  • 33
    Reynolds TB, Geller HM, Kuzma OT, Redeker AG. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 1960; 263: 734739.